Pharmacokinetics, Safety and Tolerability of Escalating Rifapentine Doses in Healthy Volunteers
Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to evaluate (1) the safety and tolerability of escalating doses of
rifapentine (RPT) administered daily by oral; (2) the effect of increasing doses of RPT on
cytochrome P450 isoform 3A (CYP3A) enzyme metabolizing activity, using single-dose midazolam
(MDZ); and (3) the effect of increasing doses of RPT on autoinduction of RPT metabolism.
Phase:
Phase 1
Details
Lead Sponsor:
Johns Hopkins University
Collaborators:
Centers for Disease Control and Prevention Sanofi
Treatments:
Midazolam Molecular Mechanisms of Pharmacological Action Rifampin Rifapentine